98 related articles for article (PubMed ID: 1231877)
1. [Interference of canrenoate potassium with plasma renin activity. Note I. Effects of canrenoate potassiumon plasma renin activity in patients with essential hypertension].
Consolo F; Ferraù O; Pitrone F; Luzza G; Russo A; Virga T
Boll Soc Ital Biol Sper; 1975 Dec; 51(24):1943-9. PubMed ID: 1231877
[No Abstract] [Full Text] [Related]
2. [Effect of potassium canrenoate on arterial pressure, plasma renin activity and urinary aldosterone in essential hypertension].
Opocher G; Armanini D; Fallo F; Mantero F
Boll Soc Ital Cardiol; 1978; 23(10):1757-66. PubMed ID: 400390
[No Abstract] [Full Text] [Related]
3. [Antihypertensive efficacy and effects on intra and extracellular electrolytes of a canrenoate potassium-butizide combination].
Costa FV; Borghi C; Mussi A; Ambrosioni E
Minerva Cardioangiol; 1988 Oct; 36(10):503-7. PubMed ID: 3226562
[No Abstract] [Full Text] [Related]
4. [Clinical study of the efficacy of oral potassium canrenoate and spironolactone in essential arterial hypertension].
Tosti-Croce C; Mantellini R; Fanti P; Sciarra F
Minerva Med; 1983 Apr; 74(14-15):791-7. PubMed ID: 6339999
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of canrenoate potassium in hypertensive cardiopathy. Clinical and echocardiographic evaluation].
Caporicci D; Achilli L
Minerva Cardioangiol; 1984 Sep; 32(9):581-7. PubMed ID: 6514202
[No Abstract] [Full Text] [Related]
6. [Value of potassium canrenoate in the prevention of arrhythmia during the acute phase of myocardial infarction].
Denis B; Machecourt J; Denis MC; Morena H; Pellet J; Rossignol B; Martin-Noël P
Arch Mal Coeur Vaiss; 1979 Sep; 72(9):1014-22. PubMed ID: 116612
[TBL] [Abstract][Full Text] [Related]
7. Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients.
Waldorff S; Buch J
Eur J Cardiol; 1979 Aug; 10(2):143-9. PubMed ID: 477703
[TBL] [Abstract][Full Text] [Related]
8. Predicting interindividual variations in antihypertensive therapy: the role of sodium transport systems and renin.
Niutta E; Cusi D; Colombo R; Pellizzoni M; Cesana B; Barlassina C; Soldati L; Bianchi G
J Hypertens Suppl; 1990 Sep; 8(4):S53-8. PubMed ID: 2175354
[TBL] [Abstract][Full Text] [Related]
9. Clinical study of potassium canrenoate on raised intracranial pressure.
Node Y; Nakazawa S
Adv Neurol; 1990; 52():557. PubMed ID: 2396562
[No Abstract] [Full Text] [Related]
10. [Effect of canrenoate potassium on intraoperative disturbances of electrolyte equilibrium].
Eschner J; Fodor L; Ahnefeld FW
Infusionsther Klin Ernahr; 1976 Apr; 3(2):98-104. PubMed ID: 965083
[TBL] [Abstract][Full Text] [Related]
11. Treatment of digitalis toxicity with intravenous potassium canrenoate.
Gavrilescu G; Cristodorescu R; Deutsch G; Berger E
Agressologie; 1977; 18(3):167-71. PubMed ID: 920909
[No Abstract] [Full Text] [Related]
12. [Study of the inotropic effect of potassium canrenoate by determining systolic time intervals].
Vitolo E; Gambini E; Larovere MT; Rusconi F; Vitali GM
Boll Soc Ital Cardiol; 1979; 24(7):775-7. PubMed ID: 554665
[No Abstract] [Full Text] [Related]
13. [Use of canrenoate potassium given orally in ascitogenic cirrhosis].
Sarti F; Milandri GL; Piemontese A; Macchia S; Simoni S; Dal Monte PR
Minerva Dietol Gastroenterol; 1984; 30(3):273-80. PubMed ID: 6504377
[No Abstract] [Full Text] [Related]
14. [Essential arterial hypertension. A therapeutic proposal].
Di Veroli C; Iugoli AR
Arch Sci Med (Torino); 1981; 138(3):355-60. PubMed ID: 6119065
[TBL] [Abstract][Full Text] [Related]
15. Selective stimulation of renal PGE2 by potassium canrenoate in essential hypertension.
Castellani S; Scarti L; Masotti G; Del Rosso A; Chen JI; Neri Serneri GG
Prog Clin Biol Res; 1989; 301():297-301. PubMed ID: 2678128
[No Abstract] [Full Text] [Related]
16. [Potassium canreonate in neurosurgical brain edema].
Mille T; Rodriguez R; Baena Y
Minerva Chir; 1975 Jul 15-31; 30(13-14):781-9. PubMed ID: 1221307
[TBL] [Abstract][Full Text] [Related]
17. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites.
Angeli P; Dalla Pria M; De Bei E; Albino G; Caregaro L; Merkel C; Ceolotto G; Gatta A
Hepatology; 1994 Jan; 19(1):72-9. PubMed ID: 8276370
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic report on an injectable aldosterone antagonist (K-canrenoate) in states of water-salf retention].
Coltorti M; Radaeli E; Ciaccio S; Corsini R; Trebbi R
Clin Ter; 1976 Feb; 76(3):215-34. PubMed ID: 963962
[No Abstract] [Full Text] [Related]
19. Sodium excretion and sodium-free volume expansion in dogs: effect of inhibition of aldosterone activity by canrenoate.
Bie P
Acta Physiol Scand; 1976 Oct; 98(2):272-4. PubMed ID: 983738
[No Abstract] [Full Text] [Related]
20. [Changes in nitrogen balance during the period following abdominal surgery and use of an injectable anti-aldosterone].
Metivier Y; Guinot P; Saizy R; Meillaud J; Lioret N
Agressologie; 1976; 17(5):313-8. PubMed ID: 1015551
[No Abstract] [Full Text] [Related]
[Next] [New Search]
